Summary: Cytochrome P450 (CYP) 1A1 is involved in the metabolic activation of polycyclic aromatic hydrocarbons (PAHs) and is induced by several compounds, including PAHs. The induction of CYP1A1 mediated by the aryl hydrocarbon receptor (AhR) has been well investigated; however, little has been reported on the mechanisms of CYP1A1 induction mediated by factors other than AhR. In this study, we investigated the involvement of liver X receptor alpha (LXR¡) in the induction of CYP1A1. TO-901317, an LXR¡ ligand, induced CYP1A1 mRNA in a dose-dependent fashion. Luciferase reporter assays using HepG2 cells showed that TO-901317 was capable of activating the promoter of the CYP1A1 gene and that a direct repeat 4 (DR4) motif located in a region from ¹452 to ¹467 was required for the induction of CYP1A1 through LXR¡. Specific binding of LXR¡ to this DR4 motif was confirmed by gel shift and chromatin immunoprecipitation assays. Co-treatment of HepG2 cells with TO-901317 and 2,3,7,8-tetrachlorodibenzo-p-dioxin, a typical AhR ligand, caused the synergistic induction of CYP1A1 mRNA. Thus, we propose that the expression of CYP1A1 is regulated by LXR¡ as well as by AhR, suggesting that exposure to both LXR¡ and AhR ligands can result in the alteration of individual susceptibility to environmental carcinogens metabolically activated by CYP1A1.
Introduction
Cytochrome P450 ¤CYP¥ monooxygenases are drugmetabolizing enzymes that play a central role in the detoxication and metabolic activation of xenobiotics.
1,2¥
Among CYP forms, CYP1A1 is known to bioactivate a variety of polycyclic aromatic hydrocarbons ¤PAHs¥, such as benzoªa«pyrene ¤Bªa«P¥, which are environmental contaminants found in tobacco smoke and diesel extract. 3¥ Interindividual variation has been noted in the inducibility of CYP1A1, and individuals who show a high inducibility of CYP1A1 were reported to have a greater risk for lung cancer. 4¥ It has been reported that expression of the CYP1A1 gene is regulated by the aryl hydrocarbon receptor ¤AhR¥, which is activated by PAHs and dioxins, including 2,3,7,8-tetrachlorodibenzo-p-dioxin ¤TCDD¥.
5,6¥ Ligand-activated AhR translocates into the nucleus, dimerizes with AhR nuclear translocator, and then binds to enhancer elements within the CYP1A1 promoter known as xenobiotic responsive elements ¤XREs¥.
7¥ Although AhR is a major regulator of CYP1A1 expression, other transcription factors belonging to the nuclear receptor family, such as the constitutive androstane receptor, peroxisome proliferator-activated receptor AE, and the retinoid acid receptor, also regulate expression of CYP1A1.
8®10¥ However, little information about the effects of other nuclear receptors on the expression of CYP1A1 has been reported so far, to the best of our knowledge.
Liver X receptor ¤LXR¥ AE is a member of the nuclear receptor superfamily that forms heterodimers with retinoid X receptor ¤RXR¥ and is activated by oxidized derivatives of cholesterol, i.e., oxysterols.
11®13¥ LXRAE is highly expressed in liver, white adipose tissues, intestine, and macrophages. 14¥ In the liver, LXRAE regulates a number of genes involved in the catabolism, transport, and efflux of cholesterol and fatty acid, including CYP7A1, sterol regulatory binding protein 1c ¤SREBP1c¥, ATP-binding cassette A1 ¤ABCA1¥, and ABCG1.
15®17¥ It has been reported that high cholesterol consumption is one of the risk factors for lung cancer in smokers. 18¥ Thus, we hypothesized that some cholesterol derivatives induce CYP1A1 through nuclear receptors other than AhR. In this study, we found that ligand-activated LXRAE is involved in the transcription of the human CYP1A1 gene.
Materials and Methods
Materials: TO-901317, 9-cis retinoid acid ¤RA¥, Bªa«P, TCDD, and Ficoll were purchased from Sigma-Aldrich ¤St. Louis, MO¥.
Cell culture: Human hepatoma-derived HepG2 cells were purchased from RIKEN BioResource Center ¤Tsukuba, Japan¥. HepG2 cells were maintained in Dulbeccoös modified Eagleös medium ¤Nissui Pharmacy, Tokyo, Japan¥ supplemented with 10% fetal bovine serum ¤BioWhittaker, Walkersville, MD¥, non-essential amino acids ¤ICN, Aurora, OH¥, and 1 mM sodium pyruvate ¤Invitrogen, Carlsbad, CA¥ at 37ôC in 5% CO 2 .
Reporter plasmids: To construct a reporter plasmid, p1A1/%1679, a 5$-flanking region from nucleotides %1679 to ¦341 relative to the transcriptional start site of the CYP1A1 gene was amplified by PCR using p1A1%1679-SacI ¤5$-TCGAGCTCTCTAGATTTGGGGCAT-3$¥ and 1A1¦ 341-HindIII ¤5$-CCCAAGCTTCCTGAAGTCCTGAAT-3$¥. The amplified fragment was digested with SacI and HindIII, and the resultant fragment was inserted into the SacI/HindIII site of pGL3 Basic Vector ¤Promega, Madison, WI¥. To generate reporter plasmids, p1A1/%989, p1A1/%692, p1A1/%614, p1A1/%540, p1A1/%430, p1A1/%330, and p1A1/%272, PCR was performed using 1A1%989-SacI ¤5$-TCGAGCTCTTCTCACGCAACGCCT-3$¥, 1A1%692-SacI ¤5$-GCGAGCTCGCGATCCTAGAGGCTG-3$¥, 1A1%614-SacI ¤5$-TCGAGCTCTCAAGAGGCGCGAAC-3$¥, 1A1% 540-SacI ¤5$-GGGAGCTCGGCCCCCGTGACCTCAG-3$¥, 1A1%430-SacI ¤5$-GCGAGCTCCTGGTAGGCTGTAGC-3$¥, 1A1%330-SacI ¤5$-AGGAGCTCGTACCCTCTCTT-CGG-3$¥ and 1A1%272-SacI ¤5$-CGGAGCTCTTCTG-CACTGCCCTT-3$¥, respectively, as sense primers and 1A1¦341-HindIII as antisense primer. p¤1A1 DR4¥ 3 -TK-LUC was constructed by inserting three copies of synthesizing oligonucleotides ¤5$-CCGGGAAGGAGGTCA-CCACGGGGCAGCCCC-3$¥ containing direct repeat 4 ¤DR4¥ in the CYP1A1 promoter. p1A1/%540 DR4mt was produced by PCR-based site-directed mutagenesis using oligonucleotides 1A1 DR4 SDM-F ¤5$-CCGGGAAGGAG-GAATCCACGCCGAAGCCCC-3$¥/1A1 DR4 SDM-R ¤5$-GGGGCTTCGGCGTGGATTCCTCCTTCCCGG-3$¥. Bold letters indicate mutated nucleotides. The expression plasmids for human LXRAE ¤pcDNA-hLXRAE¥ and RXRAE ¤pcDNA-hRXRAE¥ were constructed previously.
19¥
Transient transfection and dual-luciferase assay: HepG2 cells ¤1 ' 10 5 cells/well¥ were plated onto a 12-well plate and cultured at 37ôC overnight. Cells were transfected with each CYP1A1-luciferase reporter plasmid ¤200 ng¥ or p¤1A1 DR4¥ 3 -TK-LUC ¤200 ng¥, pcDNA-hLXRAE ¤100 ng¥, pcDNA-hRXRAE ¤100 ng¥, and with pRL-TK ¤50 ng¥ ¤Promega¥ as an internal control, by FuGENE 6 ¤Roche Diagnostics, Mannheim, Germany¥. Transfected HepG2 cells were then exposed to TO-901317 ¤10 µM¥, 9-cis RA ¤10 µM¥, and TCDD ¤10 nM¥ alone or in combination. After treatment for 36 h, cells were harvested and luciferase activities were measured using a Dual-Luciferase reporter assay system ¤Promega¥.
Gel shift assay: LXRAE and RXRAE proteins were synthesized using the TNT quick-coupled in vitro transcription/translation system ¤Promega¥. A gel shift assay was performed using double-stranded synthetic oligonucleotides labeled with ªÈ-32 P«ATP ¤Amersham Biosciences Inc., Piscataway, NJ¥ and T4 polynucleotide kinase ¤Takara Bio, Otsu, Japan¥. The binding reaction was carried out in a reaction mixture ¤10 µL¥ containing 25 mM HEPES ¤pH 7.9¥, 4% Ficoll, 40 mM KCl, 0.5 mM dithiothreitol, 0.1 mM EGTA, 1 mM MgCl 2 , 5% glycerol, poly¤dI-dC¥ ¤0.5 µg¥, 2µL in vitro-translated nuclear receptor, and 5 ' 10 4 cpm of 32 P-labeled probe DNA ¤5 fmol¥. The mixture was incubated at 4ôC for 30 min. Samples were dissolved in 0.5' Tris/borate/EDTA and applied onto a 5% non-denaturing polyacrylamide gel. The gel was electrophoresed at 100 V for 90 min at room temperature and visualized by a BAS-2500 imaging analyzer ¤Fuji Film, Tokyo, Japan¥. The sequences of oligonucleotides used for gel shift assays were as follows: 1A1 DR4, 5$-CCGGGAAGGAGGTCACCACGGGGCAGCCCC-3$, 1A1 DR4mt, 5$-CCGGGAAGGAGGAATCCACGCCGAAGC-CCC-3$, ABCA1 DR4 5$-GCGCAGAGGTTACTATCG-GTCAAA-3$.
RNA preparation and real-time quantitative PCR: HepG2 cells were treated with TO-901317 ¤1®10 µM¥ and/or 10 nM TCDD. After incubation for 24 h, total RNA was isolated using a GenElute mammalian total RNA Miniprep Kit ¤Sigma-Aldrich¥. cDNA was synthesized from total RNA ¤1 µg¥ with the 1st Strand cDNA Synthesis Kit for RT-PCR ¤AMV¥ ¤Roche Diagnostics¥. Real-time quantitative PCR for CYP1A1 and Ç-actin was carried out using a LightCycler ¤Roche Diagnostics¥ by the method described previously.
20,21¥
Chromatin immunoprecipitation ¤ChIP¥ assay: After HepG2 cells were treated with 10 µM TO-901317 or 5 µM Bªa«P for 24 h, ChIP assays were carried out using a ChIP assay kit ¤Upstate, Charlottesville, VA¥. Anti-LXRAE ¤sc-1201¥, anti-AhR ¤sc-8088¥, and normal mouse IgG ¤Santa Cruz Biotechnology, Santa Cruz, CA¥ were used to pull down formaldehyde cross-linked protein-DNA complex. DNA was extracted using a QIAquick spin column ¤Qiagen, Chatsworth, CA¥. A 2-µL portion of the extracted DNA was used as a template for PCR. The forward and reverse primers were 5$-CAAGAGGCGCGAACCTCAG-3$ and 5$-TGCCCCGTGGTGACCTCCTT-3$, respectively. The amplified products contain both 1A1 DR4 and XRE in the CYP1A1 promoter.
Results
Induction of human CYP1A1 by TO-901317 in HepG2 cells: HepG2 cells are commonly used to analyze the functions of promoters of CYP1A1 and LXRAE-target genes.
17,22®24¥ Thus, HepG2 cells were used to investigate the effects of treatment with TO-901317, a known LXRAE agonist, on CYP1A1 expression ¤Fig. 1¥. When the cells were treated with TO-901317 for 24 h, the mRNA expression of CYP1A1 was induced 2-to 3-fold in a dosedependent manner. These results suggest that LXRAE is involved in the induction of CYP1A1 expression.
Identification of region responsible for the LXRAE-mediated induction of CYP1A1: To identify the region¤s¥ responsible for the TO-901317-induced expression of the CYP1A1 gene, luciferase assays were performed using a series of 5$-deletion mutants in HepG2 cells ¤Fig. 2¥. When HepG2 cells were transfected with pcDNA-hLXRAE and treated with TO-901317, the luciferase activities seen in the cells co-transfected with p1A1/%1679, p1A1/%989, p1A1/%692, p1A1/%614, p1A1/%540, p1A1/%430, or p1A1/%330 were 12-, 7-, 10-, 14-, 10-, 2-, and 2-fold higher than that of the control, respectively. Deletion from %540 to %430 bp decreased the TO-901317-induced luciferase activity to 30% of the level seen with p1A1/%540, indicating that the region from %540 to %430 of the CYP1A1 promoter contains the sequences involved in the LXRAE-induced expression of CYP1A1. LXRAE, as a heterodimer with RXRAE, interacts with a DNA response element containing two repeats of core sequence AGGTCA. 12¥ It has been reported that LXRAE/ RXRAE heterodimer is capable of binding to a direct repeat of the nuclear receptor consensus binding site separated by four nucleotides ¤DR4¥.
13¥ Within a region from %540 to %430 of the CYP1A1 promoter, a putative LXRAE-binding site that consists of DR4 motifs, designated 1A1 DR4, was found ¤Fig. 3A¥. When mutations were introduced in 1A1 DR4 ¤p1A1/%540 DR4mt¥, the luciferase activities enhanced by ligand-activated LXRAE were reduced to 21% that of p1A1/%540 ¤Fig. 3B¥. These results suggested that 1A1 DR4 was mainly attributable to LXRAE-mediated activation of the CYP1A1 promoter. However, the reporter activity enhanced by LXRAE still remained in the mutated 1A1 DR4 ¤Fig. 3B¥, implying that another minor response element or elements may exist in the CYP1A1 promoter. We determined the ability of TO-901317 and 9-cis RA, a ligand for RXR, to activate expression through 1A1 DR4. Luciferase activity seen with p¤1A1 DR4¥ 3 -TK-LUC, containing three copies of 1A1 DR4, was induced 3-fold compared with the control by LXRAE transfection and TO-901317 treatment but not by RXRAE transfection and 9-cis RA treatment. However, treatment with 9-cis RA enhanced the TO-901317-induced luciferase activity by approximately 25-fold ¤Fig. 3C¥. These results indicate that 1A1 DR4 plays a central role in the regulation of CYP1A1 by LXRAE/RXRAE. Binding of LXRAE/RXRAE heterodimer to 1A1 DR4: To confirm the binding of LXRAE/RXRAE to 1A1 DR4, gel shift assays were carried out using in vitrotranslated LXRAE and RXRAE. Specific bands derived from the complex of LXRAE/RXRAE and 1A1 DR4 were observed, and these bands disappeared when unlabeled probes of 1A1 DR4 and DR4 in the ABCA1 promoter were added, a typical target for LXRAE/RXRAE, 25¥ but not when mutated 1A1 DR4 was added ¤Fig. 4A¥. Shifted bands derived from LXRAE/RXRAE were not observed with a mutated probe of 1A1 DR4. Furthermore, we confirmed the binding of LXRAE/RXRAE with ABCA1 DR4, and this binding competed with 1A1 DR4 cold competitor, but not with a mutated competitor of 1A1 DR4 ¤Fig. 4B¥.
To examine whether endogenous LXRAE binds to 1A1 DR4 in a genomic context, ChIP assays were conducted using HepG2 cells treated with TO-901317 or Bªa«P for 24 h ¤Fig. 5¥. We used primers that can amplify the genomic DNA region of CYP1A1 promoter containing XRE and 1A1 DR4. When immunoprecipitants obtained with anti-LXRAE antibodies from HepG2 cells treated with TO-901317 were used as a template, the specific PCR product was seen. In the case of Bªa«P treatment, the PCR product was amplified using immunoprecipitants obtained with anti-AhR antibodies. Taken together, these results indicate that LXRAE/RXRAE heterodimer binds to 1A1 DR4 of CYP1A1.
Synergistic induction of CYP1A1 mRNA by TO-901317 and TCDD: We examined the effects of cotreatment with TO-901317 and TCDD on the induction level of CYP1A1 using HepG2 cells. The expression of CYP1A1 mRNA was induced approximately 3-and 300-fold by TO-901317 and TCDD, respectively ¤Fig. 6A¥. Cotreatment with TO-901317 and TCDD resulted in a synergistic induction of CYP1A1 mRNA ¤approximately 500-to 600-fold compared to the control¥. Similar synergistic effects were observed in the reporter activities in HepG2 cells treated with TO-901317 and TCDD ¤Fig. 6B¥. TO-901317 promoted TCDD-inducible promoter activities of CYP1A1, suggesting that LXRAE would affect the induction of CYP1A1 mediated by AhR.
Discussion
CYP1A1 is involved in the bioactivation of a number of carcinogens such as PAHs. Therefore, variations in CYP1A1 induction would modulate susceptibility to cancers or other PAH-related diseases. Although transcription of CYP1A1 has been well investigated with respect to the AhR-mediated pathway, in this report, we focused on LXRAE and established that LXRAE is a novel regulator of CYP1A1.
There are some reports demonstrating that CYP1A1 may be associated with atherosclerosis. CYP1A1 mRNA is expressed in the smooth muscle cells of vessel walls and endothelial cells, and CYP1A1 is induced by PAHs in these tissues.
26,27¥ The CYP1A1 MspI polymorphism is significantly associated with higher risk for coronary artery diseases in light smokers. 28¥ In addition, the induction of CYP1A1 by PAHs has been clarified to correlate with the degree of atherosclerosis in several animals.
29,30¥ Recently, we suggested that CYP1A1 may be required for the 3-methylcholanthrene-induced suppression of mRNA expression of several genes involved in the efflux or metabolism of cholesterol. 31¥ From these reports and our current experimental results, it is suggested that the induction of CYP1A1 by LXRAE ligand may be involved in the pathogenesis of atherosclerosis, although more detailed examination is required to clarify the physiological significance of LXRAE-dependent CYP1A1 regulation. We demonstrated the synergistic effects of AhR and LXRAE agonists on the induction of CYP1A1, as shown in Figure 6 . This synergistic regulation of CYP1A1 might be associated with PAH-related cancer risk. In fact, it has been reported that high cholesterol diets contribute to a high risk for lung cancer, especially in current male smokers.
18,32¥
Those who have high levels of CYP1A1 synergistically induced by oxysterols and PAHs may produce larger quantities of reactive intermediates of PAHs derived from tobacco smoke. In contrast to the findings of our study, Savouret et al. 33¥ reported that 7-ketocholesterol, another oxysterol, suppressed both basal and TCDD-induced CYP1A1 expression levels to competitively inhibit the binding of TCDD to AhR. Further analysis is required to clarify the different effects of each LXRAE ligand on CYP1A1 induction by AhR ligands.
In summary, we found that LXRAE was involved in the induction of human CYP1A1. We also found synergy between TO-901317 and TCDD in terms of CYP1A1 induction. This novel regulation mechanism of the CYP1A1 gene may provide new insights into understanding individual susceptibility to environmental carcinogens or atherogenesis. 
